NEW YORK (TheStreet) -- UBS upgraded Immunogen (IMGN - Get Report) to "neutral" from "sell" and set a $13 price target. The firm noted a bullish outlook on Kadcyla and said royalty revenue is providing lower-risk valuation support.
The stock closed at $12.13 on Wednesday.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts